Health Capital Helsinki
  • Home
  • Why Helsinki Metropolitan
  • About
  • News
  • Events
  • Opportunities
  • Careers
  • Contact
  • Search
  • Menu Menu
Oct 15, 2020

Presenting Health Incubator Helsinki batch 1 companies:

Maculaser combats blindness

Blindness – caused by major retinal diseases – is a significant health challenge around the world. According to estimates, the global direct healthcare burden caused by retinal diseases is currently over € 400 billion. Introducing temperature-control to non-damaging retina laser is a real game-changer, believes Helsinki-based medtech company Maculaser.

Maculaser is one of the companies determined to fight blindness. By targeting retinal diseases, this medical technology company aims to radically change how the common retinopathies and age-related macular degeneration are treated in the future.

Maculaser uses non-damaging laser treatments aimed to induce regenerative effects of temperature elevation without damaging retinal tissues. Maculaser achieves safe and effective non-damaging retinal laser treatment by monitoring retinal temperature during the heating, explains Jani Tirronen, CEO, Co-Founder, at Maculaser.

Maculaser aims to radically change how the common retinopathies and age-related macular degeneration are treated in the future.

“The retina is stimulated with light pulses, and its temperature is determined from the temperature-dependent properties of the electroretinogram (ERG) responses,” he says, adding that the retinal temperature determination method enables optimal heating with high reliability.

Temperature matters

Tirronen acknowledges that so far, non-damaging laser treatments have already proven to be effective in the field of medicine, but the lack of patient-specific temperature and safety controls significantly limit the efficacy and utilization of the treatments.

“Maculaser has solved the main problem which is the real-time temperature control of the retina during these treatments,” Tirronen says. The Maculaser technology enables ophthalmologists (eye doctors) to perform optimal non-damaging laser therapy without the risk of retinal damage, he adds.

“This is a potential game-changer in the treatment of currently untreatable diseases such as dry AMD.”

Aalto innovation edge

Founded this year by Tirronen and his fellow entrepreneurs Teemu Turunen and Ossi Kaikkonen, Maculaser has roots in an Aalto University research program which started in 2013.

“Business Finland backed a commercialization program started in 2018, and in 2020 the company was set up to bring the technology and novel treatment to the markets,” Tirronen goes over the timeline.

The original Aalto research program sought a treatment for dry AMD and arrived at the conclusion that non-damaging laser treatment offers the most promising solution for managing AMD. There is strong scientific evidence that heating retinal tissue/retinal pigment epithelium (RPE) brings about a range of beneficial effects on unhealthy RPE.

Unsplash

“There is a rapidly rising positive attitude towards research-based entrepreneurship in Finland.”

Get connected!

Looking into the future, Tirronen is optimistic about the startup’s chances of making a big breakthrough in the global market.

“Retinal diseases are the leading cause of blindness and, at present, the medical need is mostly unmet. We believe we can have a major impact on the field,” he says, adding that commercial success is likely to follow proven medical excellence.

Maculaser is one of the batch 1 companies in Health Incubator Helsinki, a long-term business development environment for research-based health startups, that started operations in Helsinki in 2020. Talking about the startup’s experiences about Health Incubator Helsinki, Tirronen describes that it is about connecting with likeminded entrepreneurs as well as getting new ideas and contacts from business coaches – especially in terms of funding.

“So far, it has been an inspiring environment to operate in.”

Startup Fast Facts

Name: Maculaser

Product: Temperature-controlled non-damaging retina laser

Founded: 2020

Team size: 3

Target customer/market: 25,000 eye-clinics world-wide

Rooted in research

According to Tirronen, Finland does a good job of creating broad university and research-based innovation platforms.

“Furthermore, there is a rapidly rising positive attitude towards research-based entrepreneurship in Finland.”

In his mind, the society is relatively uncomplicated and stress-free. “Unless you’re running a startup, that is,” Tirronen grins.

More information:
Contact Maculaser
Health Incubator Helsinki – a unique long-term incubator program for research-based early stage teams and start-ups operating in the health sector in Finland and abroad

Previously published stories on Health Incubator Helsinki batch 1 companies:
Epiheart

Text: Sami J. Anteroinen
Photos and graphics: Maculaser and Unsplash

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn

Other case stories

from Greater Helsinki

Two researchers in white coats walkingKeksi Agency via City of Helsinki

TILT Biotherapeutics, rising superstar of oncolytic immunotherapy

Mar 21, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2020/04/Keksi-Agency-via-City-of-Helsinki_communications.jpg 1653 2480 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-03-21 08:00:272023-03-29 15:04:22TILT Biotherapeutics, rising superstar of oncolytic immunotherapy
Lumoral device and batteryKoite Health

Brushing your teeth is not enough – Finnish innovation reduces gingivitis efficiently

Nov 23, 2022
https://healthcapitalhelsinki.fi/wp-content/uploads/2022/11/Lumoral-laite-ja-akku-copy-res72.jpg 883 1335 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2022-11-23 14:04:292022-11-24 10:15:13Brushing your teeth is not enough – Finnish innovation reduces gingivitis efficiently
Design model of a wrist device to curb alcohol cravingsJuliana Harkki

Skin-stroking device to help curb alcohol cravings developed in Finland

https://healthcapitalhelsinki.fi/wp-content/uploads/2022/11/hentoTouch_ranne_v2_w1000.jpg 736 1000 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2022-11-14 16:13:032022-11-14 16:13:25Skin-stroking device to help curb alcohol cravings developed in Finland
All news

Other case stories

from Greater Helsinki

Mobile phone and Olo wellness appNature Solutions

Finnish startup Olo delivers the perfect sonic recharge

Sep 14, 2022
https://healthcapitalhelsinki.fi/wp-content/uploads/2022/09/Olo-app-1500x1000-1.jpg 1000 1500 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2022-09-14 08:00:462022-09-15 13:30:51Finnish startup Olo delivers the perfect sonic recharge
Medical doctor holding a phoneUnsplash

Sonai Health from Finland is on a mission to re-invent heart diagnosis

Sep 8, 2022
https://healthcapitalhelsinki.fi/wp-content/uploads/2022/08/national-cancer-institute-unsplash-1500x1000-1.jpg 1000 1500 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2022-09-08 08:20:182022-09-08 08:24:17Sonai Health from Finland is on a mission to re-invent heart diagnosis
Lab picture from NADMEDNADMED

Finnish startup NADMED measures NAD molecules for better health

Sep 1, 2022
https://healthcapitalhelsinki.fi/wp-content/uploads/2022/08/Nadmed-20-1500x1000-1.jpg 1000 1503 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2022-09-01 08:30:162022-09-01 11:44:31Finnish startup NADMED measures NAD molecules for better health
All news

Health Capital Helsinki

Helsinki Partners
Kasarmikatu 36
00130 HELSINKI
FINLAND

Privacy notice

Sign up to our newsletter

Subscribe

Follow us

  • twitter
  • linkedin
Health Capital Helsinki
Scroll to top

We use cookies to give you the best experience on our website.

Find out more and set your preferences settings.

Powered by  GDPR Cookie Compliance
How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential website cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are necessary to deliver the website as intended, refusing them will have impact how our site functions. You can always block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will prompt you to accept or refuse cookies every time you revisit our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Third party cookies

This website uses Twitter's and LinkedIn's cookies to help us improve our content and reach.

Please enable essential website cookies first so that we can save your preferences!

Privacy notice

You can read about how we use your data on our Privacy notice page.

Privacy notice